Skip to main content
. 2012 Oct 5;19(12):811–817. doi: 10.1038/cgt.2012.69

Figure 3.

Figure 3

Combined Allovectin and anti-CTLA-4 antibody immunotherapy: Tumor volume. Data from the same study shown in Figure 2 are presented, but now both control and anti-CTLA-4-treated groups are shown. Tumor volume slopes were calculated for each animal and group means compared by one-way analysis of variance (ANOVA) analyses. Synergy was then estimated as S=(μA−μB)−((μC−μB)+(μD−μB)), where A=combined treatment group, B=control group, C=9H10 alone group and D=Allovectin, VCL-1005 or dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium/dioleoyl phosphatidylethanolamine (DMRIE/DOPE) alone group. (a) Control groups only; (b) control groups (gray) and Allovectin groups; (c) control groups (gray) and VCL-1005 groups; (d) control groups (gray) and DMRIE/DOPE groups. Groups receiving no antibody (a) or SHG-1 (b–d) are shown as open symbols connected with dotted lines, while groups receiving 9H10 are shown as solid symbols connected with solid lines.